During the spring of 2026, Bryan Johnson, the man behind biohacking’s recent boom, tweeted that his partner’s vagina was "100/100." In the post that generated 21.8 million views, 20,000 likes, and 4,600 reposts (21 million of those views and 3,200 reposts within 48 hours), he shared an image of his girlfriend's vaginal microbiome summary score, exclaiming that it is in the "top 1% of all vaginas.”
Its viral moment made it one of the most amplified pieces of vaginal microbiome content ever published, and the clearest signal yet that the longevity-bro economy has arrived in women's bodies.
The numbers Johnson cites are real. Various environmental and lifestyle factors affect the composition of the vaginal microbiome, and research suggests that a dominance of the probiotic bacterium Lactobacillus crispatus is strongly linked to better vaginal health outcomes. But the framing that converts a bacterial measurement into a percentile ranking is arguably marketing logic imported from biohacking culture, reminiscent of much older politics around who gets to define a "healthy" female body.
"At-home testing in this space is primarily about closing an information gap, improving access to data that has historically been hard to obtain, whether because of practical barriers to care, stigma, or poor experiences within clinical systems," Valentina Milanova, founder and CEO of Daye, a gynecological health research company, told BeautyMatter.
Johnson is a 48-year-old tech entrepreneur who claims to spend roughly $2 million a year attempting to reverse his biological age. His partner, 30-year-old Kate Tolo, is co-founder and CMO of Blueprint, the longevity company she helped build, which complicates the narrative of consent that defenders of the post have leaned on. The internet’s take was more about public commodification of an intimate body part and less about wellness advocacy. Commenters labeled it a "cooch carfax," a "quarterly earnings report," and a partner reduced to "lab results and all."
Meanwhile, Tolo herself commented on Johnson’s tweet, defending the content by pivoting to a legitimate public-health point: oral sex carries genuine risks, which can include HSV-1 transmission, HPV-driven oropharyngeal cancers, and saliva-mediated disruption of the vaginal microbiome.
"The science is more nuanced than a viral tweet can hold," says Priyanka Jain, co-founder and CEO of Evvy, the vaginal microbiome testing company whose paid spokesperson amplified Johnson’s post. "The vaginal microbiome is deeply personal, and the health of one woman's vaginal microbiome has nothing to do with anyone else's."
Buried inside the spectacle is a real conversation about sexual health that the scoring framing actively obscures.
Johnson’s publicly published Blueprint protocol, amplified by Netflix’s 2025 Don't Die documentary, turned biometric optimization into mainstream wellness. Working with a medical team of over 30 people, he has built a personal brand around quantifying every aspect of the body, transforming optimization into both spectacle and a subscription business.
The vaginal microbiome score is simply the latest metric in that ecosystem: another intimate biological system converted into trackable performance data. However, whether the science supports Johnson’s biohacking protocols and products is open to critical question.
Johnson's tweet measures how much of Kate Tolo's existing vaginal flora is made up of a bacterial species naturally found in the human vagina and gut, Lactobacillus crispatus, meaning the score is not due to any optimization or intervention. And framing her "98.7%" as an achievement is misleading.
L. crispatus dominance has been associated with a healthier vaginal microbiome and lower risk of bacterial vaginosis (BV), high-risk HPV persistence and preterm birth, and has also been linked to better IVF outcomes. Johnson added an association with a lower risk of UTIs and other STIs to the list (even though the evidence is only suggestive), and it became the foundational thesis for every commercial vaginal microbiome test on the market.
"There is real, well-characterized biology here,” said Milanova, whose research has been published in peer-reviewed medical journals. “A vaginal microbiome dominated by Lactobacillus, and L. crispatus in particular, keeps the environment acidic and is genuinely protective. It is linked to lower rates of infection and BV, and to better pregnancy and fertility outcomes.”
But the "100/100" frame is more commercial than clinical: “These aren’t terms that we would use clinically as healthcare providers,” board-certified urogynecologist and co-founder of US company LiviWell, Dr. Michael Ingber told BeautyMatter. “The reality is, the vaginal microbiome is dynamic—it changes with menstruation, sex, semen exposure, antibiotics, pregnancy, menopause, hormones, and other factors. A L. crispatus-dominant result can be reassuring in the right context, but it is not a comprehensive measure of health, sexual function, fertility, hygiene, etc.
Dr. Betsy Greenleaf, a urogynecologist who has been using vaginal microbiome testing in clinical practice since 2009, identified the core problem: "We have to be careful not to confuse the ability to measure with the ability to interpret. The technology is ahead of our interpretation. That's not unusual in medicine. The challenge is that commercialization often doesn't wait for the science to catch up,” she told BeautyMatter.
L. crispatus dominance shifts and is shaped by hormonal state. Ingber agrees. "If a woman's score one week is 100, it's very possible that after sex, the score may be far lower due to the disruption in the microbiome that occurs. Similarly, if someone notes a score of 5, it's quite possible that two weeks later it is back up to 100.”
Jain acknowledged that L. crispatus dominance and vaginal health are not the same thing. At Evvy, they draw the line at presenting a universal definition of health, acknowledging that vaginal microbiomes naturally vary across individuals, hormone stages, symptoms, and demographics.
Black women, on average, have higher microbial diversity, higher abundance of Lactobacillus iners, and lower abundance of L. crispatus than white women—a documented population-level pattern that means Bryan Johnson's top 1% of vaginas framing is functionally a ranking against a white European phenotype.
“Race and ancestry matter in the research literature,” Ingber said. “For example, Asian women generally have the highest percentage of Lactobacillus-dominant profiles, and Black and Hispanic women generally have a lower percentage. Not every healthy patient has the same profile, and not every deviation from L. crispatus–dominance is automatically disease.”
Greenleaf stated this as one of her biggest concerns. “Medicine has a long history of creating 'normal' ranges that are actually averages of the populations being studied. Laboratory normals are not necessarily ideals; they're statistical averages of who was included in the data set,” she said.
“We have to be careful not to inadvertently suggest that one microbiome profile is superior to another simply because it is more common in one population that has historically been overrepresented in research studies,” Greenleaf added. “If we don't acknowledge the variability, we risk pathologizing normal human diversity.”
Jain agreed: "Historically, medicine has often defined 'normal' based on narrow datasets that excluded diverse populations, and that's the kind of problem we're actively trying to avoid repeating." Milanova noted that it matters more for people underserved by traditional pathways, including LGBTQ+ and trans people who require gynecological care.
Understanding the imperative, Evvy has invested heavily in building large-scale, real-world datasets, as precision medicine for underrepresented communities cannot exist without diverse demographics. Its current patient population closely matches the racial distribution of the US, according to Jain.
Meanwhile, the market reductively treats all vaginas the same.
The vaginal microbiome testing market reached $159.99 million in 2025 and is projected to reach $250.05 million by 2030 at a compound annual growth rate of 9.34%. It’s a small but fast-growing femtech category that sits inside a far larger commercial ecosystem: the broader feminine intimate care market—lubricants, washes, and microbiome-supportive products—valued at $7.8 billion in 2024 and projected to reach $14 billion by 2034.
In 2021, Evvy raised $5 million in seed funding to explicitly address the women's health data gap through metagenomic sequencing; in 2023, the company raised a further $14 million in Series A funding to scale its platform, expand into STI care, and leverage AI to explore molecular signatures for female health. The company launched EvvyAI in May 2026, calling it the first AI advisor for vaginal health built on the world's largest vaginal microbiome dataset.
Ob-gyn Jen Gunter published an in-depth critique of Evvy in 2021, arguing that the company is "exploiting" the gender health gap rather than closing it: that vaginal microbiome results have no clinical actionability for asymptomatic users, that Evvy's "personalized wellness plan" amounts to "practicing medicine" without the data to support it, and that the real product is the dataset Evvy is building from paying customers.
Jain was clear that EvvyAI does not itself generate medical guidance. All diagnoses and treatment plans remain with licensed clinicians. She also confirmed, however, that over time the platform's dataset is being used to predict which care plans are most likely to improve individual patient outcomes, with those predictions fed back to clinicians as guidance. The AI, in other words, sits upstream of the clinical decision, not outside it.
Greenleaf delved further into the commercial conflict embedded in the model: "If they are offering other products and supplements as a treatment option, we enter a level of conflict of interest, where it would be in their best interest for the client to 'have a problem' that can be treated with a product they are making money off of,” she said.
The platform Johnson used to score Kate Tolo's microbiome was Tiny Health, a US-based at-home testing brand that sits alongside Evvy and Juno Bio in a category whose growth depends on consumers willing to pay for ongoing measurement.
In 2025, UK-based Juno Bio raised $4.6 million in seed funding to expand its at-home testing platform, which confirmed the category’s global growth stage. In 2026, LiviWell secured FDA clearance to launch Livi, a single-use polyurethane foam device inserted vaginally after intercourse to absorb semen, which completes the commercial arc from scoring vaginal microbiomes as percentiles to selling women disposable products to clean up after the unprotected sex that disrupts them.
The category’s tension isn't lost on Evvy's founder: "The vaginal microbiome is not a game, a leaderboard, or a universal measure of health…. Instead of focusing on competition or optimization theater, the conversation should be focused on research, destigmatization, and building solutions that actually improve the health outcomes women care about,” Jain said.
Milanova stressed that the point is not a perfect number: “It is understanding whether your microbiome sits in a protective state or a disrupted one, and knowing what to do about it. The science on how best to shift it is still developing, which is exactly why a result needs proper interpretation and follow-up care rather than a supplement recommendation stapled to it,” she pointed out before stating that the opportunity for brands in this space is to capitalize on the awareness and turn it into transformative research and real support.
Yet with the wider women's health market projected to grow from $49.33 billion in 2024 to $68.53 billion by 2030, with femtech specifically forecast at $103 billion by 2030, the category expansion has piqued male-led longevity’s interest in women's bodies. Enter: vaginamaxxing.
According to a 2024 McKinsey report, women spend 25% more time in poor health compared to men due to diagnostic delays, lack of tailored treatments, and historic underinvestment in conditions that disproportionately affect women—a data gap that the longevity-bro economy is actively moving to monetize, rather than close.
"The longevity conversation, for all its blind spots, has done one genuinely useful thing," Milanova explained. "It has made people comfortable testing and tracking their own biology. The problem is that women's bodies, and reproductive health in particular, have been almost entirely left out of it."
Female-led longevity and menopause companies like Midi, Elektra, and Nuchido explicitly position themselves against the bro-biohacking framing, though they have yet to achieve the same cultural reach as Johnson and his peers.
To Greenleaf, women's physiology is cyclical, dynamic, adaptive, and deeply interconnected. "The menstrual cycle changes things. Pregnancy changes things. Stress changes things. Aging changes things. Menopause changes things. Women are not static machines waiting to be optimized,” she said.
Female-facing longevity discourse is increasingly translating longevity-bro logic onto reproductive biology itself, with public personas like influencer Kayla Barnes-Lentz describing the ovaries as "the pacemaker of longevity.”
Barnes-Lentz shared her own vaginal microbiome report on Instagram in support of the Johnson tweet, telling USA Today, "I'm thrilled that he posted that…. Women are suffering too much, and we have to just speak about it more,” which positioned the public scoring of women's bodies as a feminist intervention.
By May 2026, the optimization logic Johnson's tweet amplified had acquired a consumer-culture name: vaginamaxxing, defined by clinicians as attempts to "improve" the appearance, smell, tightness, grooming, or perceived attractiveness of the vulva or vagina through beauty routines, supplements, procedures, or products.
"Women arrive in my office already worried before we've even started the conversation," Greenleaf said. "They'll say things like, 'My score was low,' or 'My microbiome is broken,' or 'I have bacteria that aren't supposed to be there.' We've unintentionally created a language where women begin to see themselves as defective because an app, report, or proprietary algorithm assigned a number to a very dynamic biological system." Sometimes Greenleaf spends more time deconstructing anxiety generated by a report than she does addressing the woman's actual symptoms. “We have to be careful that technology doesn't turn healthy women into worried patients,” she continued.
Yet the clinical consequences are already visible. For years, women were dismissed from medical discourse due to a lack of data. Now women are drowning in data they don’t fully understand. “The vaginal microbiome holds enormous scientific promise. But promise is not the same thing as proof,” Greenleaf added.
The beauty industry has turned its attention inward—from skin to hormones to gut—and now the vaginal microbiome is being scored and sold back to women as self-improvement.
Johnson’s tweet didn’t create the logic; it just made visible what the wellness economy had already decided: that no part of a woman’s body is too intimate to be optimized, too complex to be scored, or too personal to be commodified into a product.